Lawsuit Alleges GLP-1 Weight Loss Drugs Cause Permanent Vision Loss
A multi-district lawsuit, comprising over 130 cases, is currently before a Philadelphia judge, claiming that popular GLP-1 medications are linked to a rare and permanent form of vision loss. The lawsuit targets drug manufacturers Novo Nordisk and Eli Lilly, producers of widely prescribed medications such as Wegovy, Ozempic, Mounjaro, and Zepbound. The core of these lawsuits, including one filed in Massachusetts, revolves around non-arteritic anterior ischemic optic neuropathy (NAION), an irreversible condition often described as an eye stroke resulting from restricted blood flow. A 2024 study published in JAMA Ophthalmology by researchers at Mass Eye and Ear in Boston indicated that diabetic patients prescribed GLP-1 medications were more than four times more likely to be diagnosed with NAION, while overweight patients taking the drugs were more than seven times more likely to receive the diagnosis. Attorney Jason Goldstein, serving on the multi-district lawsuit steering committee, highlighted that NAION s... 
